EUVIMEDEUVIMED entdecken
Open Access

Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients

Myrsini Ioakeim-Ioannidou, Andrzej Niemierko, Daniel W Kim, Athena Tejada, Tobias Urell, Shannon Leahy, Judy Adams, Barbara Fullerton, G Petur Nielsen, Yin P Hung iD, Angela R Shih, Manuel Patino und 13 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Myrsini Ioakeim-Ioannidou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Chordoma, Skull Base Neoplasms, Chondrosarcoma, Proton Therapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Radium Society, American Society for Radiation Oncology, Harvard Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on clinical outcomes for base of skull (BOS) chordomas in the pediatric population is limited. We report patient outcomes after surgery and proton radiotherapy (PRT).

Methods

Pediatric patients with BOS chordomas were treated with PRT or combined proton/photon approach (proton-based; for most, 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Endpoints of interest were overall survival (OS), disease-specific survival, progression-free survival (PFS), freedom from local recurrence (LC), and freedom from distant failure (DC).

Results

Of 204 patients, median age at diagnosis was 11.1 years (range, 1–21). Chordoma location included 59% upper and/or middle clivus, 36% lower clivus, 4% craniocervical junction, and 1% nasal cavity. Fifteen (7%) received pre-RT chemotherapy. Forty-seven (23%) received PRT, and 157 (77%) received comboRT. Median total dose was 76.7 Gy (RBE) (range, 59.3–83.3). At a median follow-up of 10 years (interquartile range, 5–16 years), 56 recurred. Median OS and PFS were 26 and 25 years, with 5-, 10-, and 20-year OS and PFS rates of 84% and 74%, 78% and 69%, and 64% and 64%, respectively. Multivariable actuarial analyses showed poorly differentiated subtype, radiographical progression prior to RT, larger treatment volume, and lower clivus location to be prognostic factors for worse OS, PFS, and LC. RT was well tolerated at a median follow-up of 9 years (interquartile range, 4–16 years). Side effects included 166 patients (80%) with mild/moderate acute toxicities, 24 (12%) patients with late toxicities, and 4 (2%) who developed secondary radiation-related malignancies.

Conclusion

This is the largest cohort of BOS chordomas in the literature, pediatric and/or adult. High-dose PRT following surgical resection is effective with low rates of late toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChordomaSkull Base NeoplasmsChondrosarcomaProton TherapyAdultHumansChildInfantChild, PreschoolAdolescentYoung AdultProtonsSkull BaseTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Pediatric chordomaadverse effectsproton radiotherapyskull basesurvival

Substanzen

Protons

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Department of Pediatric Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Yin P Hung

Förderung

  • American Radium Society
  • American Society for Radiation Oncology
  • Harvard Medical School

Zitieren

APA

Ioakeim-Ioannidou, M., Niemierko, A., Kim, D. W., Tejada, A., Urell, T., Leahy, S., Adams, J., Fullerton, B., Nielsen, G. P., Hung, Y. P., Shih, A. R., Patino, M., Buch, K., Rincon, S., Kelly, H., Cunnane, M. B., Tolia, M., Widemann, B. C., Wedekind, M. F., …, & MacDonald, S. M. (2023). Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad068

Vancouver

Ioakeim-Ioannidou M, Niemierko A, Kim DW, Tejada A, Urell T, Leahy S, et al. Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad068

BibTeX
@article{IoakeimIoannidou2023,
  author = {Ioakeim-Ioannidou, Myrsini and Niemierko, Andrzej and Kim, Daniel W and Tejada, Athena and Urell, Tobias and Leahy, Shannon and Adams, Judy and Fullerton, Barbara and Nielsen, G Petur and Hung, Yin P and Shih, Angela R and Patino, Manuel and Buch, Karen and Rincon, Sandra and Kelly, Hilary and Cunnane, Mary Beth and Tolia, Maria and Widemann, Brigitte C and Wedekind, Mary F and John, Liny and Ebb, David and Shin, John H and Cote, Gregory and Curry, William and MacDonald, Shannon M},
  title = {Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad068}
}
Kostenlos starten →